Skip to main content

Table 2 Clinicopathological characteristics of HCC patients (n = 21)

From: The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma

Clinical Characteristics

Variables

Available data (n)

n (%)

Age, years

20–30/30–40/40–50/50–60/60–70/ > 70

21

2(9.52%)/2(9.52%)/7(33.3%)/5(23.8%)/4(19.0%)/5(23.8%)

Gender

Male/Female

21

18(85.7%)/3(14.3%)

TNM

T1bN0M0/T2N0M0/T4N0M0/T4N1M1

11

6(54.5%)/1(9.0%)/3(27.3%)/1(9.0%)

BCLC

0/A/B/C

14

1(7.1%)/7(50.0%)/2(14.3%)/4(28.6%)

Immunohistochemistry

GPC3(+)/ GPC3(−)

13

7(53.8%)/6(46.2%)

Hep-1(+)/ Hep-1(−)/None

18

11(61.1%)/1(5.5%)/6(33.3%)

CD34(+)/CD34(−)/None

18

10(55.6%)/2(11.1%)/6(33.3%)

HBsAg(+)/HBsAg(−)

18

14(77.8%)/4(22.2%)

Arginase(+)/Arginase(−)/None

18

8(44.4%)/1(5.5%)/9(50.0%)

AMACR(+)/AMACR(−)/None

18

8(44.4%)/5(27.8%)/5(27.8%)

CK7(+)/CK7(−)

18

1(5.5%)/17(94.4%)

GS(+)/GS(−)

18

2(11.1%)/16(88.9%)

HSP70(+)/HSP70(−)

18

11(61.1%)/7(38.9%)

CD10(+)/CD10(−)

18

2(11.1%)/16(88.9%)

CK19(+)/CK19(−)

18

1(5.5%)/17(94.4%)

CD31(+)/None

18

9(50.0%)/9(50.0%)